Pilocytic Astrocytoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Childhood Visual Pathway GliomaIntervention: Drug: lenalidomideSponsor: National Cancer Institute (NCI)Suspended - verified June 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2012 Category: Research Source Type: clinical trials
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1; Recurrent Childhood Pilocytic Astrocytoma; Recurrent Childhood Visual Pathway GliomaInterventions: Drug: Lenalidomide; Other: Pharmacological StudySponsor: National Cancer Institute (NCI)Suspended - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 10, 2012 Category: Research Source Type: clinical trials
